| 121st Maine Legislature | |||||||
| Office of Fiscal and Program Review | |||||||
| LD 254 | |||||||
| An Act To Require Full Disclosure of Prescription Drug Marketing Costs | |||||||
| LR 0072(01) | |||||||
| Fiscal Note for Original Bill | |||||||
| Sponsor: Rep. Kane | |||||||
| Committee: Health and Human Services | |||||||
| Fiscal Note Required: Yes | |||||||
| Fiscal Note | |||||||
| Undetermined current biennium cost increase - Other Special Revenue Funds | |||||||
| Undetermined current biennium revenue increase - Other Special Revenue Funds | |||||||
| Minor cost increase - General Fund | |||||||
| Minor revenue increase - General Fund | |||||||
| Correctional and Judicial Impact Statements | |||||||
| Establishes new civil violation | |||||||
| Fiscal Detail and Notes | |||||||
| Any initial start-up costs to the Bureau of Medical Services in the Department of Human Services can be absorbed within existing budgeted resources. The bill requires prescription drug manufacturers pay fees to the Department in addition to submitting reports. The amount of these fees are to be determined by the Department. The timing and amount of revenue collected from these fees, as well as the ongoing costs of the Department can not be determined at this time. The bill assumes the fees will be sufficient to cover additional costs to the Department. Any additional costs to the Office of the Attorney General can be absorbed within existing budgeted resources. | |||||||